Matthew Lebsack
Family Medicine · Delta, CONPI 1144640517
Payments from drug & device makers
Across 131 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$632
- GSK$516
- AstraZeneca$290
- Pfizer$197
- Astellas Pharma US Inc$188
- Lilly USA, LLC$143
- plus $523 from 15 others
What the payments were for
- Food & beverage$2,490100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 35 | $632 |
| GSK | 24 | $516 |
| AstraZeneca | 17 | $290 |
| Pfizer | 10 | $197 |
| Astellas Pharma US Inc | 9 | $188 |
| Lilly USA, LLC | 9 | $143 |
| Biohaven Pharmaceuticals, Inc. | 5 | $98 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Mylan Specialty L.p. | 2 | $50 |
| Novo Nordisk | 2 | $40 |
| Amgen | 2 | $37 |
| Exact Sciences | 2 | $37 |
| Johnson & Johnson | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Insulet Corporation | 1 | $22 |
| Organogenesis Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Boehringer Ingelheim | 1 | $13 |
How this compares
$2,490 in reported general payments places this provider in the 85th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 132 | $186,116 |
| MounjaroTirzepatide | 72 | $107,764 |
| XareltoRivaroxaban | 70 | $104,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $94,852 |
| FarxigaDapagliflozin Propanediol | 66 | $83,971 |
| OzempicSemaglutide | 56 | $75,239 |
| TrulicityDulaglutide | 43 | $45,161 |
| Spiriva RespimatTiotropium Bromide | 38 | $35,097 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $30,846 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $28,143 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $16,947 |
| Arnuity ElliptaFluticasone Furoate | 44 | $13,655 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 40 | $12,600 |
| JardianceEmpagliflozin | 13 | $12,165 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $11,227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $197 | $186,116132 claims |
| Lilly USA, LLCMounjaro, Trulicity | $143 | $152,925115 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $290 | $131,764142 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Anoro Ellipta, Breo Ellipta | $516 | $125,093173 claims |
| Johnson & JohnsonXarelto | $33 | $104,33770 claims |
| Novo NordiskOzempic, Novolog | $40 | $78,27271 claims |
| Boehringer IngelheimSpiriva Respimat, Jardiance | $13 | $47,26251 claims |
| AbbVieUbrelvy, Synthroid | $632 | $13,19638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Delta
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Timothy ColanderAurora$3.1M
- Mia ScottDenver$993K
- Matthew LewisAurora$960K
- Ethan LazarusDenver$688K
- Patrick BarryFraser$568K
- Astrid LampeyFraser$568K
- Kari UusinarkausWoodland Park$520K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.